HLN Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 8.37% compared to Haleon PLC's net margin of 21.46%. Haleon PLC's return on equity of 8.91% beat AstraZeneca PLC's return on equity of 19.55%.

Haleon PLC has a consensus price target of $11.56, signalling upside risk potential of 11.34%. On the other hand AstraZeneca PLC has an analysts' consensus of $84.18 which suggests that it could grow by 20.52%. Given that AstraZeneca PLC has higher upside potential than Haleon PLC, analysts believe AstraZeneca PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.385, suggesting its less volatile than the S&P 500 by 61.545%.

Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.63%. AstraZeneca PLC offers a yield of 2.22% to investors and pays a quarterly dividend of $1.05 per share. Haleon PLC pays 39.53% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are smaller than AstraZeneca PLC quarterly revenues of $13.6B. Haleon PLC's net income of $295.8M is lower than AstraZeneca PLC's net income of $2.9B. Notably, Haleon PLC's price-to-earnings ratio is 25.80x while AstraZeneca PLC's PE ratio is 28.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.32x versus 3.97x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Haleon PLC has a consensus price target of $11.56, signalling upside risk potential of 11.34%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1962.52%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Haleon PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Haleon PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.210, suggesting its more volatile than the S&P 500 by 21.022%.

Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.63%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Haleon PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 25.80x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.32x versus 0.91x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

GSK PLC has a net margin of 8.37% compared to Haleon PLC's net margin of 21.61%. Haleon PLC's return on equity of 8.91% beat GSK PLC's return on equity of 23.08%.

Haleon PLC has a consensus price target of $11.56, signalling upside risk potential of 11.34%. On the other hand GSK PLC has an analysts' consensus of $41.54 which suggests that it could grow by 7.66%. Given that Haleon PLC has higher upside potential than GSK PLC, analysts believe Haleon PLC is more attractive than GSK PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.283%.

Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.63%. GSK PLC offers a yield of 4.15% to investors and pays a quarterly dividend of $0.43 per share. Haleon PLC pays 39.53% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are smaller than GSK PLC quarterly revenues of $9.5B. Haleon PLC's net income of $295.8M is lower than GSK PLC's net income of $2B. Notably, Haleon PLC's price-to-earnings ratio is 25.80x while GSK PLC's PE ratio is 20.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.32x versus 1.98x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

Smith & Nephew PLC has a net margin of 8.37% compared to Haleon PLC's net margin of --. Haleon PLC's return on equity of 8.91% beat Smith & Nephew PLC's return on equity of 7.88%.

Haleon PLC has a consensus price target of $11.56, signalling upside risk potential of 11.34%. On the other hand Smith & Nephew PLC has an analysts' consensus of $33.15 which suggests that it could grow by 9.7%. Given that Haleon PLC has higher upside potential than Smith & Nephew PLC, analysts believe Haleon PLC is more attractive than Smith & Nephew PLC.

Haleon PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Smith & Nephew PLC has a beta of 0.677, suggesting its less volatile than the S&P 500 by 32.318%.

Haleon PLC has a quarterly dividend of $0.12 per share corresponding to a yield of 1.63%. Smith & Nephew PLC offers a yield of 2.48% to investors and pays a quarterly dividend of $0.46 per share. Haleon PLC pays 39.53% of its earnings as a dividend. Smith & Nephew PLC pays out 79.37% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Haleon PLC quarterly revenues are $3.5B, which are larger than Smith & Nephew PLC quarterly revenues of --. Haleon PLC's net income of $295.8M is higher than Smith & Nephew PLC's net income of --. Notably, Haleon PLC's price-to-earnings ratio is 25.80x while Smith & Nephew PLC's PE ratio is 32.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon PLC is 3.32x versus 2.28x for Smith & Nephew PLC. Usually stocks with elevated PS ratios are considered overvalued.